Arrowhead Pharmaceuticals, Inc. (A2RR34.SA)
Chart Events
Performance Outlook
| Previous Close | 16.50 |
| Open | 0.00 |
| Bid | 16.36 x N/A |
| Ask | 26.33 x N/A |
| Day's Range | 16.50 - 16.50 |
| 52 Week Range | 16.38 - 26.07 |
| Volume | |
| Avg. Volume | 15 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.58 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for A2RR34.SA
Related Research
Business WireArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif., September 27, 2023--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 26, 2023, the Company’s Board of Directors approved "inducement" grants to 47 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 81,350 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans an
GuruFocus.comInsider Sell: CEO Christopher Anzalone Sells 57,755 Shares of Arrowhead Pharmaceuticals Inc
On September 18, 2023, Christopher Anzalone, the CEO of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR), sold 57,755 shares of the company.
Business WireArrowhead Presents Data on Pulmonary Pipeline at ERS 2023
PASADENA, Calif., September 11, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, including clinical results for ARO-RAGE, being presented at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy. In an ongoing Phase 1/2 clinical trial, ARO-RAGE, Arrowhead’s investigational RNAi therapeutic for the treatment of inflammatory lung diseases, achieved mean target
